MRNA

$249.509.22%21.06

Moderna Inc (MRNA)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$228.44

Aprire:

$235.00

Volume 24 ore:

6,502,200

Volume relativo:

0.38

Capitalizzazione di mercato:

$99.61B

Reddito:

$2.23B

Utile/perdita netta:

-$3.19B

Rapporto P/E:

EPS:

-$8.15

Flusso di cassa netto:

-$1.60B

1W Prestazione:

+16.50%

1M Prestazione:

+31.31%

6M Prestazione:

+427.48%

1Y Prestazione:

+950.53%

Intervallo 1D:

$230.21$253.72

Intervallo di 1 settimana:

$215.35$235.50

Portata 52W:

$22.28$254.48

Profilo aziendale di Moderna Inc (MRNA)

Nome

Moderna Inc

Settore

Healthcare

Industria

Biotechnology

Telefono

(617) 714-6500

Indirizzo

325 BINNEY STREET, CAMBRIDGE, USA

Dipendente

4,700

@moderna_tx

Prossima data di guadagno

2026-11-06

Ultimi documenti SEC

SEC

Discussioni di MRNA su X

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Moderna Inc Azioni (MRNA) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-10-27	Downgrade	William Blair	Outperform → Mkt Perform
2026-09-30	Downgrade	Citigroup	Neutral → Sell
2026-09-03	Downgrade	Rothschild & Co Redburn	Neutral → Sell
2026-08-28	Aggiornamento	Argus	Hold → Buy
2026-08-25	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2026-08-19	Aggiornamento	BofA Securities	Underperform → Neutral
2026-08-19	Aggiornamento	William Blair	Mkt Perform → Outperform
2026-01-28	Resumed	Barclays	Equal Weight
2026-01-07	Resumed	UBS	Neutral
2025-12-12	Iniziato	Jefferies	Hold
2025-03-13	Iniziato	Citigroup	Neutral
2025-02-18	Downgrade	Barclays	Overweight → Equal Weight
2025-01-29	Downgrade	Goldman	Buy → Neutral
2024-12-18	Downgrade	Argus	Buy → Hold
2024-12-10	Resumed	BofA Securities	Underperform
2024-11-19	Iniziato	Berenberg	Hold
2024-11-18	Aggiornamento	HSBC Securities	Hold → Buy
2024-11-15	Iniziato	Wolfe Research	Underperform
2024-10-17	Iniziato	Bernstein	Mkt Perform
2024-09-13	Downgrade	JP Morgan	Neutral → Underweight
2024-09-13	Downgrade	Jefferies	Buy → Hold
2024-09-13	Downgrade	Oppenheimer	Outperform → Perform
2024-08-28	Aggiornamento	HSBC Securities	Reduce → Hold
2024-08-07	Aggiornamento	Deutsche Bank	Sell → Hold
2024-08-05	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2024-02-26	Downgrade	HSBC Securities	Hold → Reduce
2024-01-02	Aggiornamento	Oppenheimer	Perform → Outperform
2023-11-29	Iniziato	Canaccord Genuity	Hold
2023-11-03	Aggiornamento	HSBC Securities	Reduce → Hold
2023-11-02	Downgrade	Deutsche Bank	Hold → Sell
2023-08-04	Downgrade	TD Cowen	Outperform → Market Perform
2023-08-03	Downgrade	Deutsche Bank	Buy → Hold
2023-07-24	Iniziato	William Blair	Mkt Perform
2023-07-14	Iniziato	HSBC Securities	Reduce
2023-06-26	Aggiornamento	UBS	Neutral → Buy
2023-04-26	Iniziato	Guggenheim	Neutral
2023-03-13	Aggiornamento	TD Cowen	Market Perform → Outperform
2023-03-02	Iniziato	RBC Capital Mkts	Outperform
2023-02-24	Downgrade	SVB Securities	Market Perform → Underperform
2022-12-19	Aggiornamento	Jefferies	Hold → Buy
2022-12-14	Downgrade	Chardan Capital Markets	Buy → Neutral
2022-10-21	Aggiornamento	SVB Leerink	Underperform → Mkt Perform
2022-09-08	Aggiornamento	Deutsche Bank	Hold → Buy
2022-02-01	Aggiornamento	Redburn	Sell → Neutral
2022-01-26	Aggiornamento	Deutsche Bank	Sell → Hold
2022-01-21	Aggiornamento	BofA Securities	Underperform → Neutral
2022-01-21	Iniziato	UBS	Neutral
2021-12-07	Iniziato	Cowen	Market Perform
2021-11-09	Iniziato	Wolfe Research	Outperform
2021-10-22	Iniziato	Deutsche Bank	Sell
2021-10-15	Aggiornamento	Piper Sandler	Neutral → Overweight
2021-08-06	Downgrade	Oppenheimer	Outperform → Perform
2021-08-06	Downgrade	Piper Sandler	Overweight → Neutral
2021-07-15	Reiterato	Jefferies	Hold
2021-02-01	Downgrade	BofA Securities	Neutral → Underperform
2020-12-16	Downgrade	Jefferies	Buy → Hold
2020-12-16	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-12-09	Downgrade	Needham	Buy → Hold
2020-11-23	Iniziato	Wells Fargo	Equal Weight
2020-11-17	Downgrade	BMO Capital Markets	Outperform → Market Perform
2020-09-08	Downgrade	SVB Leerink	Mkt Perform → Underperform
2020-07-23	Iniziato	SVB Leerink	Mkt Perform
2020-07-20	Downgrade	JP Morgan	Overweight → Neutral
2020-07-13	Iniziato	Jefferies	Buy
2020-06-30	Iniziato	Argus	Buy
2020-06-08	Iniziato	Barclays	Overweight
2020-04-30	Iniziato	BMO Capital Markets	Outperform
2020-03-05	Downgrade	BofA/Merrill	Buy → Neutral
2019-12-03	Resumed	BofA/Merrill	Buy
2019-10-25	Iniziato	ROTH Capital	Buy
2019-04-05	Iniziato	Chardan Capital Markets	Buy

Moderna Inc Azioni (MRNA) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	1,944.00	3,236.00	6,848.00	19,263.00	18,471.00
Cost of revenue USD (M)	868.00	1,464.00	4,693.00	5,416.00	2,617.00
Gross profit USD (M)	-	-	2,155.00	13,847.00	15,854.00
Research and development USD (M)	3,132.00	4,543.00	4,845.00	3,295.00	1,991.00
Operating expenses USD (M)	5,018.00	7,181.00	6,394.00	4,427.00	2,558.00
Operating income USD (M)	-3,074.00	-3,945.00	-4,239.00	9,420.00	13,296.00
Income before tax USD (M)	-2,768.00	-3,607.00	-3,942.00	9,575.00	13,285.00
Income tax expense USD (M)	54.00	-46.00	772.00	1,213.00	1,083.00
Net income USD (M)	-2,822.00	-3,561.00	-4,714.00	8,362.00	12,202.00
Basic EPS USD/shares	-7.26	-9.28	-12.33	21.26	30.31
Diluted EPS USD/shares	-7.26	-9.28	-12.33	20.12	28.29
Basic weighted shares shares (M)	389.00	384.00	382.00	394.00	403.00
Diluted weighted shares shares (M)	389.00	384.00	382.00	416.00	431.00

Moderna Inc Azioni (MRNA) insider trading

Hoge StephenOct 15 '26
President
Transazione
Option Exercise
Costo
$12.21
#Azioni
76,452
Valore ($)
933,479
#Azioni Totale
1,675,710
Hoge StephenOct 15 '26
Officer
Transazione
Proposed Sale
Costo
$220.72
#Azioni
39,145
Valore ($)
8,640,033
#Azioni Totale
0
Hoge StephenOct 15 '26
President
Transazione
Sale
Costo
$220.72
#Azioni
39,145
Valore ($)
8,640,084
#Azioni Totale
1,636,565
Hoge StephenOct 14 '26
President
Transazione
Option Exercise
Costo
$12.21
#Azioni
76,453
Valore ($)
933,491
#Azioni Totale
1,638,482
Hoge StephenOct 14 '26
President
Transazione
Sale
Costo
$213.48
#Azioni
39,224
Valore ($)
8,373,453
#Azioni Totale
1,599,258
Hoge StephenOct 14 '26
Officer
Transazione
Proposed Sale
Costo
$213.48
#Azioni
39,224
Valore ($)
8,373,519
#Azioni Totale
0
Hoge StephenSep 15 '26
Officer
Transazione
Proposed Sale
Costo
$146.07
#Azioni
40,281
Valore ($)
5,883,709
#Azioni Totale
0
Hoge StephenSep 15 '26
President
Transazione
Option Exercise
Costo
$12.21
#Azioni
76,452
Valore ($)
933,479
#Azioni Totale
1,602,310
Hoge StephenSep 15 '26
President
Transazione
Sale
Costo
$146.07
#Azioni
40,281
Valore ($)
5,883,846
#Azioni Totale
1,562,029
Hoge StephenSep 14 '26
Officer
Transazione
Proposed Sale
Costo
$144.13
#Azioni
40,294
Valore ($)
5,807,746
#Azioni Totale
0

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Hoge Stephen	President	Oct 15 '26	Option Exercise	$12.21	76,452	933,479	1,675,710
Hoge Stephen	Officer	Oct 15 '26	Proposed Sale	$220.72	39,145	8,640,033	0
Hoge Stephen	President	Oct 15 '26	Sale	$220.72	39,145	8,640,084	1,636,565
Hoge Stephen	President	Oct 14 '26	Option Exercise	$12.21	76,453	933,491	1,638,482
Hoge Stephen	President	Oct 14 '26	Sale	$213.48	39,224	8,373,453	1,599,258
Hoge Stephen	Officer	Oct 14 '26	Proposed Sale	$213.48	39,224	8,373,519	0
Hoge Stephen	Officer	Sep 15 '26	Proposed Sale	$146.07	40,281	5,883,709	0
Hoge Stephen	President	Sep 15 '26	Option Exercise	$12.21	76,452	933,479	1,602,310
Hoge Stephen	President	Sep 15 '26	Sale	$146.07	40,281	5,883,846	1,562,029
Hoge Stephen	Officer	Sep 14 '26	Proposed Sale	$144.13	40,294	5,807,746	0

Moderna Inc Borsa (MRNA) Ultime notizie

Nov 03, 2026

Could Investing in Moderna's Stock Double Your Money? - The Motley Fool

Nov 03, 2026

Nov 02, 2026

Chubb Trades at $369.07, Setting Back-to-Back Record Highs - 24/7 Wall St.

Nov 02, 2026

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna - BioSpace

Nov 02, 2026

Amgen Just Gave Its Shareholders Great News - The Motley Fool

Nov 02, 2026

Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts? - Zacks Investment Research

Nov 02, 2026

Buy Moderna Stock Before Q3 Earnings? Here's What to Know - Zacks Investment Research

Nov 02, 2026

If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started - The Motley Fool

Nov 02, 2026

Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook - Zacks Investment Research

Oct 30, 2026

Oct 29, 2026

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth? - Zacks Investment Research

Oct 29, 2026

MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up - Zacks Investment Research

Oct 29, 2026

Will Moderna Soar on Nov. 6? - The Motley Fool

Oct 29, 2026

Oct 28, 2026

Will Moderna (NASDAQ:MRNA) Cost Cuts Strengthen Its Business Recovery? - Kalkine Media

Oct 28, 2026

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility - The Motley Fool

Oct 28, 2026

Oct 27, 2026

Is Moderna (NASDAQ:MRNA) Facing a Reality Check After Its Rally? - Kalkine Media

Oct 27, 2026

Moderna, Inc. (MRNA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 27, 2026

Oct 26, 2026

Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? - The Motley Fool

Oct 26, 2026

Breakfast News: Science Strikes Back at Cancer - The Motley Fool

Oct 26, 2026

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? - Zacks Investment Research

Oct 26, 2026

Oct 25, 2026

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool

Oct 25, 2026

Oct 24, 2026

Breakfast News: A Conversation With Moderna’s CEO - The Motley Fool

Oct 24, 2026

Oct 23, 2026

American Tower (AMT) jumps 8% at the open, towering over a 385-stock board - 24/7 Wall St.

Oct 23, 2026

Moderna’s Stock Just Stumbled. Is It a Buy on the Dip? - The Motley Fool

Oct 23, 2026

Moderna Wins Top Employer Status - Baystreet.ca

Oct 23, 2026

Capital Group Global Growth (CGGO) Buys $121.1 Million More Moderna on Oct. 21 - Yahoo Finance

Oct 23, 2026

Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research

Oct 23, 2026

Oct 22, 2026

Chubb Breaks to a New 52-Week High at $363.95 - 24/7 Wall St.

Oct 22, 2026

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports - The Motley Fool

Oct 22, 2026

Moderna Sheds $12 Billion in a Single Session After a 14% Drop - 24/7 Wall St.

Oct 22, 2026

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool

Oct 22, 2026

Oct 21, 2026

Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 - The Motley Fool

Oct 21, 2026

Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice - The Motley Fool

Oct 21, 2026

Oct 20, 2026

Moderna MRNA Breaks to a New 52-Week High at $242.08 - 24/7 Wall St.

Oct 20, 2026

Merck & (MRK) Stock Price, News & Analysis - 24/7 Wall St.

Oct 20, 2026

Oct 18, 2026

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? - The Motley Fool

Oct 18, 2026

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors. - The Motley Fool

Oct 18, 2026

Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027? - The Motley Fool

Oct 18, 2026

Oct 17, 2026

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline - The Motley Fool

Oct 17, 2026

The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going - The Motley Fool

Oct 17, 2026

Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com Australia

Oct 17, 2026

Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com Nigeria

Oct 17, 2026

Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com UK

Oct 17, 2026

Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com Canada

Oct 17, 2026

Oct 16, 2026

Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? - The Motley Fool

Oct 16, 2026

Oct 15, 2026

Moderna Executive Stephen Hoge Announces Intent to Sell 39,145 Shares Under Rule 144 - Kalkine Media

Oct 15, 2026

Oct 13, 2026

MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research

Oct 13, 2026

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Oct 13, 2026

Oct 12, 2026

Here's Why Moderna (MRNA) Fell More Than Broader Market - Zacks Investment Research

Oct 12, 2026

Simile a MRNA

Moderna Inc (MRNA)

Profilo aziendale di Moderna Inc (MRNA)

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Moderna Inc Azioni (MRNA) Upgrade e downgrade

Moderna Inc Azioni (MRNA) Dati Finanziari

Moderna Inc Azioni (MRNA) insider trading

Moderna Inc Borsa (MRNA) Ultime notizie

Could Investing in Moderna's Stock Double Your Money? - The Motley Fool

Chubb Trades at $369.07, Setting Back-to-Back Record Highs - 24/7 Wall St.

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna - BioSpace

Amgen Just Gave Its Shareholders Great News - The Motley Fool

Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts? - Zacks Investment Research

Buy Moderna Stock Before Q3 Earnings? Here's What to Know - Zacks Investment Research

If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started - The Motley Fool

Breakfast News: We’re Right There With You - The Motley Fool

Stock Split Watch: Is Moderna Next? - The Motley Fool

Can Moderna (NASDAQ:MRNA) Turn a Flu Shot Into a Better Report? - Kalkine Media

Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook - Zacks Investment Research

GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth? - Zacks Investment Research

MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock Up - Zacks Investment Research

Will Moderna Soar on Nov. 6? - The Motley Fool

Will Moderna (NASDAQ:MRNA) Cost Cuts Strengthen Its Business Recovery? - Kalkine Media

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility - The Motley Fool

Is Moderna (NASDAQ:MRNA) Facing a Reality Check After Its Rally? - Kalkine Media

Moderna, Inc. (MRNA) Stock Price, News, Quote & History - Yahoo! Finance Canada

Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? - The Motley Fool

Breakfast News: Science Strikes Back at Cancer - The Motley Fool

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? - Zacks Investment Research

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool

Breakfast News: A Conversation With Moderna’s CEO - The Motley Fool

American Tower (AMT) jumps 8% at the open, towering over a 385-stock board - 24/7 Wall St.

Moderna’s Stock Just Stumbled. Is It a Buy on the Dip? - The Motley Fool

Moderna Wins Top Employer Status - Baystreet.ca

Capital Group Global Growth (CGGO) Buys $121.1 Million More Moderna on Oct. 21 - Yahoo Finance

Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research

Chubb Breaks to a New 52-Week High at $363.95 - 24/7 Wall St.

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports - The Motley Fool

Moderna Sheds $12 Billion in a Single Session After a 14% Drop - 24/7 Wall St.

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool

Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 - The Motley Fool

Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice - The Motley Fool

Moderna MRNA Breaks to a New 52-Week High at $242.08 - 24/7 Wall St.

Merck & (MRK) Stock Price, News & Analysis - 24/7 Wall St.

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? - The Motley Fool

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors. - The Motley Fool

Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027? - The Motley Fool

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline - The Motley Fool

The Nasdaq-100's 6 Best Stocks This Year, and Whether They Can Keep Going - The Motley Fool

Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com Australia

Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com Nigeria

Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com UK

Form 4 Moderna Inc: Stephen Hoge (President) For: 14 October By Investing.com - Investing.com Canada

Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy? - The Motley Fool

Moderna Executive Stephen Hoge Announces Intent to Sell 39,145 Shares Under Rule 144 - Kalkine Media

MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Here's Why Moderna (MRNA) Fell More Than Broader Market - Zacks Investment Research

Simile a MRNA